TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25045795
Drug: Cathejell lubricant
Normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathejell lubricant with lidocaine 12.5g administered immediately before cystoscopy
Study: 17327338
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg q.d. and 60 mg b.i.d.
Study: 16083193
Drug: Creatine supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplement (5 g with orange solution 15 g, twice per day for 7 days)
Study: 16083193
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (orange solution only)
Study: 8922007
Drug: Subcutaneous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous lidocaine (SQL) pretreatment
Study: 1550365
Drug: D‐penicillamine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐penicillamine (maximum dose of 750 mg/d)
Study: 2931846
Drug: Chrysanol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chrysanol (1.5 ml of a 5% solution)
Study: 2931846
Drug: Myochrysine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myochrysine (50 mg, 25 mg metallic gold once a week)
Study: 28169258
Drug: Adjunctive photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive photodynamic therapy (PDT) using 810 nm diode laser and Indocyanine green as photosensitizer
Study: 25453731
Drug: Statins (3‐hydroxy‐3‐methylglutaryl‐coenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitors) ± ezetimibe
Study: 12002352
Drug: Intravesical oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical oxybutynin (5 mg/30 ml three times daily)
Study: 9813559
Drug: L‐NMMA (nitric
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (nitric oxide synthase inhibitor)
Study: 7653804
Drug: Alfentanil 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 50 micrograms/kg as a rapid infusion over 10 min during CPB (normothermic)
Study: 7653804
Drug: Alfentanil 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 50 micrograms/kg as a rapid infusion over 10 min during CPB (hypothermic)
Study: 7653804
Drug: Alfentanil 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 50 micrograms/kg as a rapid infusion over 10 min (nonbypass group)
Study: 2496420
Drug: Placebo gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gum (0 mg)
Study: 828982
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: saline solution (1000‐1500 ml), glucose (100‐150 g), and amino acids (15‐30 g) per day
Study: 828982
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: 40‐50 Cal/kg per day (dextrose about 15 g/kg per day), about 2 g of amino acids/kg/day and about 40‐50 ml water/kg/day
Study: 828982
Drug: Hyperalimentation (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperalimentation (both treatments sequentially)
Study: 29154057
Drug: Far-infrared ray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Far-infrared ray (FIR) patches applied to 98 MTrPs for 24 hours in the intervention group (61 patients)
Study: 29154057
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches applied to 91 MTrPs in the control group (57 patients)
Study: 24458801
Drug: Rosuvastatin (RSV)
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin (RSV) 10 mg/d plus Ezetimibe (EZT) 10 mg/d
Study: 24458801
Drug: Rosuvastatin (RSV)
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin (RSV) 10 mg/d and Ezetimibe (EZT) 10 mg/d
Study: 21330640
Drug: Valsartan (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (320 mg daily)
Study: 19387176
Drug: Sugammadex (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (16 mg/kg) administered 3 min after rocuronium (1.2 mg/kg)
Study: 17291177
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of an inert placebo described as a suspected environmental toxin
Study: 14699004
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ramipril (10 mg/d) and atorvastatin (40 mg/d)
Study: 8445234
Drug: alpha-interferon with
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alpha-interferon with or without steroid priming
Study: 3725503
Drug: Standard magnesium-aluminum
Normalized name: Magnesium Aluminum Silicate
DrugBank: Magnesium Aluminum Silicate (DB11230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard magnesium-aluminum hydroxide antacids at a dose of 0.5 mL/kg per dose
Study: 30630801
Drug: Breast-conserving therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conserving therapy integrated with neoadjuvant chemotherapy
Study: 28667881
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy (wait-list group)
Study: 18507868
Drug: BB therapy
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: BB therapy with thrice-daily insulin aspart and once-daily basal insulin (BB group)
Study: 18507868
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with twice-daily biphasic insulin analogue (30 Mix group)
Study: 10379622
Drug: Higher nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher nicotine yield cigarettes (1.1 mg nicotine yield)
Study: 10379622
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low nicotine yield cigarette (0.05 mg nicotine yield)
Study: 8950781
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC) with low estrogen formulations containing norgestimate or gestodene
Study: 1850722
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose chemotherapy (60 mg/m2 doxorubicin and 500 mg/m2 5-fluorouracil every 3 weeks)
Study: 1850722
Drug: 131I antiferritin
Normalized name: iobenguane (131I)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 131I antiferritin administration every 8 weeks
Study: 1850722
Drug: 131I antiferritin
Normalized name: iobenguane (131I)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 131I antiferritin administration
Study: 21779745
Drug: Tooth/implant supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth/implant supported restoration
Study: 21779745
Drug: Implant only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant only restoration
Study: 19508580
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel applied to the wound twice a day for 60 days after removal of stitches
Study: 12819247
Drug: High-dose dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dialysis
Study: 12819247
Drug: Standard-dose dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose dialysis
Study: 12490682
Drug: Dose and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose and flux interventions
Study: 7616311
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplementation (20 mg/kg body wt) in young adult women
Study: 7616311
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplementation (2.5 g/kg diet) in Sprague-Dawley rats
Study: 7616311
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplementation (3 g/kg diet) in guinea pigs
Study: 203998
Drug: Corticotropin (ACTH)
Normalized name: corticotropin Injectable Solution [ACTH Gel]
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticotropin (ACTH) 80 units intramuscularly daily
Study: 203998
Drug: Hydrocortisone 400
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 400 mg infused intravenously over 24 hours
Study: 22500381
Drug: Erzhi Tiangui
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erzhi Tiangui Granule combined with Western medicine
Study: 16225522
Drug: Lidocaine suppositories
Normalized name: lidocaine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine suppositories (60 mg) applied 1 or 2 hours before biopsy
Study: 16225522
Drug: Lidocaine suppositories
Normalized name: lidocaine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine suppositories (60 mg) applied 1 hour before biopsy
Study: 16225522
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (2% - 200 mg) applied 10 minutes before biopsy
Study: 10432030
Drug: Vaccine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (30 microg each of gB2 and gD2, administered at months 0, 1, and 6)
Study: 8642806
Drug: Rilmenidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine (2 mg)
Study: 2155756
Drug: Otomize spray
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Otomize spray (neomycin/dexamethasone), administered 3 times daily for 10 days
Study: 2155756
Drug: Otosporin drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otosporin drops (neomycin/polymyxin B/hydrocortisone), administered 3 times daily for 10 days
Study: 7435249
Drug: Melperone, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperone, 50 mg i.v.
Study: 26446479
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 μg kg(‐1) hr(‐1))
Study: 17846068
Drug: Facio‐oral tract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facio‐oral tract therapy for three weeks (15 sessions of 1 hour each)
Study: 15142200
Drug: Esomeprazole 2
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 2 x 20 mg
Study: 15142200
Drug: Esomeprazole 1
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 1 x 40 mg
Study: 12575590
Drug: Huancongdan capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huancongdan capsule (HCDC)
Study: 9389288
Drug: Intranasal glucocorticoid
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal glucocorticoid (beclomethasone dipropionate, 400 microg/day)
Study: 8317687
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg acetylsalicylic acid (ASA) daily
Study: 8317687
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg acetylsalicylic acid (ASA) daily
Study: 8317687
Drug: Both dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosage groups (40 mg and 500 mg)
Study: 26063325
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 10 mg per week (FA10)
Study: 26063325
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 30 mg per week (FA30)
Study: 21572992
Drug: Adrenaline (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline (0.25 ml of a 1:1,000 solution subcutaneously)
Study: 21572992
Drug: Hydrocortisone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (200 mg intravenously)
Study: 16790616
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) 3 mg/kg
Study: 12627741
Drug: National Institute
Normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: National Institute on Drug Abuse standard condition
Study: 10696738
Drug: Concurrent intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concurrent intra-arterial infusion of platinum drugs with radiation therapy (IAPRT)
Study: 6388315
Drug: Sulfamethoxazole-trimethoprim (oral)
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfamethoxazole-trimethoprim (oral) for 14 days
Study: 6388315
Drug: Pentamidine (intramuscular)
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentamidine (intramuscular) for 14 days
Study: 30691177
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two sensors (pocket and wrist)
Study: 11300507
Drug: MDMA 100
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 100 mg as a single oral dose
Study: 6240223
Drug: norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfloxacin (400 mg) twice daily for 10 days
Study: 3070683
Drug: trimethoprim‐sulfamethoxazole (160‐800
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim‐sulfamethoxazole (160‐800 mg) twice daily for 10 days
Study: 30341453
Drug: SC abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SC abatacept 125 mg/week plus methotrexate (MTX)
Study: 26630643
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (ER-niacin)
Study: 23874021
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (20 mg/wk)
Study: 12876632
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists for 3 months
Study: 12876632
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists for 6 months
Study: 12876632
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment durations (3 months and 6 months)
Study: 3330116
Drug: 40 mg/die
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/die slow release nifedipine
Study: 31647124
Drug: Treatment response
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment response (continued-improvers)
Study: 31647124
Drug: Treatment response
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment response (halted-improvers)
Study: 23931044
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion (0.5 mmol/kg bolus followed by 0.2 mmol/kg/hour infusion)
Study: 20494931
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (control group)
Study: 12785458
Drug: Tramadol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (75 mg or 112.5 mg) plus Acetaminophen (650 mg or 975 mg)
Study: 12785458
Drug: Tramadol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (75 mg or 112.5 mg)
Study: 12785458
Drug: Acetaminophen (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (650 mg or 975 mg)
Study: 30303612
Drug: Tramadol/Acetaminophen combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/Acetaminophen combination
Study: 10687148
Drug: Cohort 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: high-dose cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by peripheral blood stem cell infusion and granulocyte colony-stimulating factor at 10 micrograms/kg
Study: 10687148
Drug: Cohort 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2: CTCb plus rhIL-2 (2 x 10(6) IU/m2/day) for 4 days intravenously via continuous infusion after peripheral blood stem cell infusion
Study: 10687148
Drug: Cohort 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 3: CTCb followed by infusion of autologous activated NK cells and rhIL-2 (2 x 10(6) IU/m2/day) for 4 days via continuous intravenous infusion
Study: 8567973
Drug: Low-dose (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (0.025 U/kg) infusion over 10 min
Study: 8567973
Drug: Low-dose (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (0.025 U/kg) bolus injection
Study: 8567973
Drug: High-dose (0.050
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (0.050 U/kg) bolus injection
Study: 2872054
Drug: Propranolol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (8 mg i.v.)
Study: 2872054
Drug: Pindolol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (0.8 mg i.v.)
Study: 29538506
Drug: Control (Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Standard Medical Treatment)
Study: 25168488
Drug: Stable background
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable background AD medication
Study: 25168488
Drug: Control-arm data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control-arm data (placebo and stable background AD medication)
Study: 19674789
Drug: cediranib (RECENTIN™)
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cediranib (RECENTIN™) at doses of ≤30 mg/day
Study: 18279553
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol esters mixed with vegetable oil spreads (2 g/d)
Study: 15752828
Drug: Virosomal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosomal vaccine (Epaxal)
Study: 15752828
Drug: Aluminum-adsorbed vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-adsorbed vaccine (Havrix 1440)
Study: 12883493
Drug: peginterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2b 1.5 mcg per kg and ribavirin for 48 weeks
Study: 10583450
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 100 IU daily, increased to 1600 IU daily
Study: 8934240
Drug: Routine monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Routine monthly changes of percutaneous feeding tubes
Study: 1875728
Drug: Low therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low therapeutic dosage of methionyl‐human growth hormone (met‐hGH)
Study: 1875728
Drug: High therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High therapeutic dosage of methionyl‐human growth hormone (met‐hGH)
Study: 1875728
Drug: Methionyl‐human growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionyl‐human growth hormone (met‐hGH) supplementation
Study: 26923616
Drug: Immediate auditory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate auditory feedback therapy
Study: 26923616
Drug: Jittered auditory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jittered auditory feedback therapy
Study: 25275520
Drug: Pomegranate fruit
Normalized name: Pomegranate Fruit
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate fruit extract and galangal rhizome (Punalpin) tablets taken daily for three months
Study: 25275520
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets taken daily for three months
Study: 16189518
Drug: S-1 2-week
Normalized name: (S)-1-phenyl-2-aminopropane
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 2-week administration followed by 1-week rest for 6 months (arm A)
Study: 16189518
Drug: S-1 4-week
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S-1 4-week administration followed by 2-week rest for 6 months (arm B)
Study: 2100969
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiotherapy combination
Study: 2100969
Drug: Portal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Portal infusion of cytotoxic drugs
Study: 28094477
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)
Study: 28094477
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion)
Study: 28094477
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine (0.5 µg/kg loading, 0.4 µg/kg/h infusion)
Study: 19289630
Drug: Methotrexate 40
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 40 mg/m2 intravenously weekly
Study: 15235059
Drug: L‐DOPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐DOPA
Study: 20634797
Drug: Quinapril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (40 mg/day)
Study: 7917794
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of atenolol (50 mg) and nifedipine (20 mg)
Study: 3057810
Drug: Genotropin (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotropin (recombinant somatropin) with 6-7 injections/week
Study: 3057810
Drug: Genotropin (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotropin (recombinant somatropin) with 2-3 injections/week
Study: 22253268
Drug: Dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% in Ringer lactate solution
Study: 22253268
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate solution (control)
Study: 21897343
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with local anesthetic, lidocaine 0.5%, 10 mL
Study: 21897343
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with 0.5% lidocaine, 9 mL, mixed with 1 mL of steroid